TRDA Stock Analysis: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$13.48
0.86 (6.81%)
▲
5d:
+11.87%
30d:
+13.76%
90d:
+33.6%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TRDA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TRDA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $13.48, which is considered extended relative to its 30-day fair value range of $11.60 to $12.86.
Technical Outlook: Technically, TRDA is in a uptrend. The price is approaching resistance at $13.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.8% recently.
Market Sentiment: TRDA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.00 (+48.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TRDA is in a uptrend. The price is approaching resistance at $13.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.8% recently.
Market Sentiment: TRDA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.00 (+48.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$11.60 -
$12.86
Company Quality Score
64/100
(BUY)
Options IV Signal
35th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
68.8%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 35th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.8%)
- BULLISH: Trading 48.4% below Wall St target ($20.00)
Fair Price Analysis
30-Day Fair Range
$11.60 -
$12.86
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$2.06
(15.3%)
Support & Resistance Levels
Support Level
$10.97
Resistance Level
$13.19
Current Trend
Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.85
Wall Street Target
$20.00
(+48.4%)
Revenue Growth (YoY)
-96.5%
Share & Embed Analysis
Last updated: April 02, 2026 7:40 AM ET
Data refreshes hourly during market hours. Next update: 8:40 AM
Data refreshes hourly during market hours. Next update: 8:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
3
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Nathan J Dowden
SELL
11894 shares
2026-03-10
Kory James Wentworth
SELL
11388 shares
2026-03-10
Kory James Wentworth
SELL
5089 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 45 HOLD |